{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:17:49Z","timestamp":1784308669707,"version":"3.55.0"},"reference-count":176,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2023A1515140148"],"award-info":[{"award-number":["2023A1515140148"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ningxia Key R&D Program","award":["2022CMG02041"],"award-info":[{"award-number":["2022CMG02041"]}]},{"name":"the High-level Talent Research Funding Program of the First Dongguan Affiliated Hospital of Guangdong Medical University","award":["GCC2023004"],"award-info":[{"award-number":["GCC2023004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11010-025-05329-5","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T04:23:09Z","timestamp":1750652589000},"page":"5345-5367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The challenges and progress of CAR-T cell therapy in the treatment of solid tumors"],"prefix":"10.1007","volume":"480","author":[{"given":"Kai","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songshan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-4171","authenticated-orcid":false,"given":"Muhammad Asad","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0481-9625","authenticated-orcid":false,"given":"Guangxian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"5329_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ctrv.2017.01.008","volume":"54","author":"J Martin-Liberal","year":"2017","unstructured":"Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J (2017) The expanding role of immunotherapy. Cancer Treat Rev 54:74\u201386. https:\/\/doi.org\/10.1016\/j.ctrv.2017.01.008","journal-title":"Cancer Treat Rev"},{"key":"5329_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41571-025-00993-4","volume":"22","author":"RG Faramand","year":"2025","unstructured":"Faramand RG, Locke FL (2025) Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R\/R B-ALL. Nat Rev Clin Oncol 22:161\u2013162. https:\/\/doi.org\/10.1038\/s41571-025-00993-4","journal-title":"Nat Rev Clin Oncol"},{"key":"5329_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107158","volume":"203","author":"K Hadiloo","year":"2024","unstructured":"Hadiloo K, Taremi S, Safa SH, Amidifar S, Esmaeilzadeh A (2024) The new era of immunological treatment, last updated and future consideration of CAR T cell-based drugs. Pharmacol Res 203:107158. https:\/\/doi.org\/10.1016\/j.phrs.2024.107158","journal-title":"Pharmacol Res"},{"key":"5329_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejphar.2009.09.067","volume":"625","author":"H Borghaei","year":"2009","unstructured":"Borghaei H, Smith MR, Campbell KS (2009) Immunotherapy of cancer. Eur J Pharmacol 625:41\u201354. https:\/\/doi.org\/10.1016\/j.ejphar.2009.09.067","journal-title":"Eur J Pharmacol"},{"key":"5329_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480\u2013489. https:\/\/doi.org\/10.1038\/nature10673","journal-title":"Nature"},{"key":"5329_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s0065-2776(06)90008-x","volume":"90","author":"AJ Korman","year":"2006","unstructured":"Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297\u2013339. https:\/\/doi.org\/10.1016\/s0065-2776(06)90008-x","journal-title":"Adv Immunol"},{"key":"5329_CR7","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1078-0432.Ccr-18-2743","volume":"25","author":"N Bouchkouj","year":"2019","unstructured":"Bouchkouj N, Kasamon YL, de Claro RA, George B, Lin X, Lee S, Blumenthal GM, Bryan W, McKee AE, Pazdur R (2019) FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res 25:1702\u20131708. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2743","journal-title":"Clin Cancer Res"},{"key":"5329_CR8","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","volume":"233","author":"SA Rosenberg","year":"1986","unstructured":"Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318\u20131321. https:\/\/doi.org\/10.1126\/science.3489291","journal-title":"Science"},{"key":"5329_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH (2020) CRISPR-engineered T cells in patients with refractory cancer. Science. https:\/\/doi.org\/10.1126\/science.aba7365","journal-title":"Science"},{"key":"5329_CR10","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/2201352a0","volume":"220","author":"I Hellstr\u00f6m","year":"1968","unstructured":"Hellstr\u00f6m I, Hellstr\u00f6m KE, Pierce GE, Yang JP (1968) Cellular and humoral immunity to different types of human neoplasms. Nature 220:1352\u20131354. https:\/\/doi.org\/10.1038\/2201352a0","journal-title":"Nature"},{"key":"5329_CR11","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1073\/pnas.96.10.5340","volume":"96","author":"DM Pardoll","year":"1999","unstructured":"Pardoll DM (1999) Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 96:5340\u20135342. https:\/\/doi.org\/10.1073\/pnas.96.10.5340","journal-title":"Proc Natl Acad Sci USA"},{"key":"5329_CR12","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734\u20131736. https:\/\/doi.org\/10.1126\/science.271.5256.1734","journal-title":"Science"},{"issue":"Suppl 8","key":"5329_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jdv.15992","volume":"33","author":"MC Liebl","year":"2019","unstructured":"Liebl MC, Hofmann TG (2019) Identification of responders to immune checkpoint therapy: which biomarkers have the highest value? J Eur Acad Dermatol Venereol 33(Suppl 8):52\u201356. https:\/\/doi.org\/10.1111\/jdv.15992","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5329_CR14","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.2174\/1871530321666210310142141","volume":"21","author":"M Mohsenzadegan","year":"2021","unstructured":"Mohsenzadegan M, Bavandpour P, Nowroozi MR, Amini E, Kourosh-Arami M, Momeni SA, Bokaie S, Sharifi L (2021) The potential of T cell immunoglobulin and mucin-domain containing-3 (Tim-3) in designing novel immunotherapy for bladder cancer. Endocr Metab Immune Disord Drug Targets 21:2131\u20132146. https:\/\/doi.org\/10.2174\/1871530321666210310142141","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"5329_CR15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/ni967","volume":"4","author":"WK Suh","year":"2003","unstructured":"Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, Duncan GS, Bukczynski J, Plyte S, Elia A, Wakeham A, Itie A, Chung S, Da Costa J, Arya S, Horan T, Campbell P, Gaida K, Ohashi PS, Watts TH, Yoshinaga SK, Bray MR, Jordana M, Mak TW (2003) The B7 family member B7\u2013H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 4:899\u2013906. https:\/\/doi.org\/10.1038\/ni967","journal-title":"Nat Immunol"},{"key":"5329_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/sj.gene.6364171","volume":"6","author":"Z Zhang","year":"2005","unstructured":"Zhang Z, Duvefelt K, Svensson F, Masterman T, Jonasdottir G, Salter H, Emahazion T, Hellgren D, Falk G, Olsson T, Hillert J, Anvret M (2005) Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis. Genes Immun 6:145\u2013152. https:\/\/doi.org\/10.1038\/sj.gene.6364171","journal-title":"Genes Immun"},{"key":"5329_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6:1245\u20131252. https:\/\/doi.org\/10.1038\/ni1271","journal-title":"Nat Immunol"},{"key":"5329_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, Shalaby MN, Thangavelu L, Kamrava S, Shomali N, Sohrabi AD, Adili A, Noroozi-Aghideh A, Razeghian E (2022) Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 20:44. https:\/\/doi.org\/10.1186\/s12964-022-00854-y","journal-title":"Cell Commun Signal"},{"key":"5329_CR19","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2:1346\u20131353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051","journal-title":"JAMA Oncol"},{"key":"5329_CR20","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28:2377\u20132385. https:\/\/doi.org\/10.1093\/annonc\/mdx286","journal-title":"Ann Oncol"},{"key":"5329_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"5329_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canlet.2019.10.013","volume":"468","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Zhan H (2020) Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett 468:72\u201381. https:\/\/doi.org\/10.1016\/j.canlet.2019.10.013","journal-title":"Cancer Lett"},{"key":"5329_CR23","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.molmed.2021.06.005","volume":"27","author":"G Lucibello","year":"2021","unstructured":"Lucibello G, Mograbi B, Milano G, Hofman P, Brest P (2021) PD-L1 regulation revisited: impact on immunotherapeutic strategies. Trends Mol Med 27:868\u2013881. https:\/\/doi.org\/10.1016\/j.molmed.2021.06.005","journal-title":"Trends Mol Med"},{"key":"5329_CR24","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","volume":"252","author":"RL Martuza","year":"1991","unstructured":"Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854\u2013856. https:\/\/doi.org\/10.1126\/science.1851332","journal-title":"Science"},{"key":"5329_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.trecan.2023.09.012","volume":"10","author":"K DePeaux","year":"2024","unstructured":"DePeaux K, Delgoffe GM (2024) Integrating innate and adaptive immunity in oncolytic virus therapy. Trends Cancer 10:135\u2013146. https:\/\/doi.org\/10.1016\/j.trecan.2023.09.012","journal-title":"Trends Cancer"},{"key":"5329_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","volume":"6","author":"J Raja","year":"2018","unstructured":"Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS (2018) Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer 6:140. https:\/\/doi.org\/10.1186\/s40425-018-0458-z","journal-title":"J Immunother Cancer"},{"key":"5329_CR27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/77558","volume":"6","author":"DF Stojdl","year":"2000","unstructured":"Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6:821\u2013825. https:\/\/doi.org\/10.1038\/77558","journal-title":"Nat Med"},{"key":"5329_CR28","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/sj.gt.3302971","volume":"14","author":"X Fu","year":"2007","unstructured":"Fu X, Tao L, Zhang X (2007) An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells. Gene Ther 14:1218\u20131225. https:\/\/doi.org\/10.1038\/sj.gt.3302971","journal-title":"Gene Ther"},{"key":"5329_CR29","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/gt.2009.1","volume":"16","author":"T Nishimoto","year":"2009","unstructured":"Nishimoto T, Yoshida K, Miura Y, Kobayashi A, Hara H, Ohnami S, Kurisu K, Yoshida T, Aoki K (2009) Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob. Gene Ther 16:669\u2013680. https:\/\/doi.org\/10.1038\/gt.2009.1","journal-title":"Gene Ther"},{"key":"5329_CR30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/gt.2012.44","volume":"20","author":"T Sugiyama","year":"2013","unstructured":"Sugiyama T, Yoneda M, Kuraishi T, Hattori S, Inoue Y, Sato H, Kai C (2013) Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Gene Ther 20:338\u2013347. https:\/\/doi.org\/10.1038\/gt.2012.44","journal-title":"Gene Ther"},{"key":"5329_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1586\/ecp.12.53","volume":"5","author":"AJ Black","year":"2012","unstructured":"Black AJ, Morris DG (2012) Clinical trials involving the oncolytic virus, reovirus: ready for prime time? Expert Rev Clin Pharmacol 5:517\u2013520. https:\/\/doi.org\/10.1586\/ecp.12.53","journal-title":"Expert Rev Clin Pharmacol"},{"key":"5329_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","volume":"13","author":"AI Freeman","year":"2006","unstructured":"Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS, Galun E, Siegal T (2006) Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13:221\u2013228. https:\/\/doi.org\/10.1016\/j.ymthe.2005.08.016","journal-title":"Mol Ther"},{"key":"5329_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1471-2407-12-99","volume":"12","author":"K Geletneky","year":"2012","unstructured":"Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, Dahm M, Krebs O, von Knebel DM, Huber B, Hajda J (2012) Phase I\/IIa study of intratumoral\/intracerebral or intravenous\/intracerebral administration of parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 12:99. https:\/\/doi.org\/10.1186\/1471-2407-12-99","journal-title":"BMC Cancer"},{"key":"5329_CR34","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1158\/1078-0432.Ccr-18-4022","volume":"25","author":"NE Annels","year":"2019","unstructured":"Annels NE, Mansfield D, Arif M, Ballesteros-Merino C, Simpson GR, Denyer M, Sandhu SS, Melcher AA, Harrington KJ, Davies B, Au G, Grose M, Bagwan I, Fox B, Vile R, Mostafid H, Shafren D, Pandha HS (2019) Phase I Trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. Clin Cancer Res 25:5818\u20135831. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-4022","journal-title":"Clin Cancer Res"},{"key":"5329_CR35","doi-asserted-by":"publisher","first-page":"638","DOI":"10.15252\/emmm.201607296","volume":"9","author":"KG Potts","year":"2017","unstructured":"Potts KG, Irwin CR, Favis NA, Pink DB, Vincent KM, Lewis JD, Moore RB, Hitt MM, Evans DH (2017) Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models. EMBO Mol Med 9:638\u2013654. https:\/\/doi.org\/10.15252\/emmm.201607296","journal-title":"EMBO Mol Med"},{"key":"5329_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1089\/hum.2021.29150.mmu","volume":"32","author":"M Muhuri","year":"2021","unstructured":"Muhuri M, Gao G (2021) Oncolytic virus alphavirus M1: a new and promising weapon to fight cancer. Hum Gene Ther 32:136\u2013137. https:\/\/doi.org\/10.1089\/hum.2021.29150.mmu","journal-title":"Hum Gene Ther"},{"key":"5329_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","volume":"4","author":"H Rehman","year":"2016","unstructured":"Rehman H, Silk AW, Kane MP, Kaufman HL (2016) Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer 4:53. https:\/\/doi.org\/10.1186\/s40425-016-0158-5","journal-title":"J Immunother Cancer"},{"key":"5329_CR38","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3389\/fonc.2020.01786","volume":"10","author":"GD Cao","year":"2020","unstructured":"Cao GD, He XB, Sun Q, Chen S, Wan K, Xu X, Feng X, Li PP, Chen B, Xiong MM (2020) The oncolytic virus in cancer diagnosis and treatment. Front Oncol 10:1786. https:\/\/doi.org\/10.3389\/fonc.2020.01786","journal-title":"Front Oncol"},{"key":"5329_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cells12172159","author":"M Kaczmarek","year":"2023","unstructured":"Kaczmarek M, Pozna\u0144ska J, Fechner F, Michalska N, Paszkowska S, Napiera\u0142a A, Mackiewicz A (2023) Cancer vaccine therapeutics: limitations and effectiveness\u2014a literature review. Cells. https:\/\/doi.org\/10.3390\/cells12172159","journal-title":"Cells"},{"key":"5329_CR40","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#","volume":"55","author":"HC Hoover Jr","year":"1985","unstructured":"Hoover HC Jr, Surdyke MG, Dangel RB, Peters LC, Hanna MG Jr (1985) Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55:1236\u20131243","journal-title":"Cancer"},{"key":"5329_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","volume":"20","author":"L Miao","year":"2021","unstructured":"Miao L, Zhang Y, Huang L (2021) mRNA vaccine for cancer immunotherapy. Mol Cancer 20:41. https:\/\/doi.org\/10.1186\/s12943-021-01335-5","journal-title":"Mol Cancer"},{"key":"5329_CR42","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.apsb.2020.08.004","volume":"11","author":"Y Yang","year":"2021","unstructured":"Yang Y, Guo X, Hu B, He P, Jiang X, Wang Z, Zhu H, Hu L, Yu M, Feng M (2021) Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses. Acta Pharm Sin B 11:476\u2013487. https:\/\/doi.org\/10.1016\/j.apsb.2020.08.004","journal-title":"Acta Pharm Sin B"},{"key":"5329_CR43","doi-asserted-by":"publisher","first-page":"534","DOI":"10.4161\/hv.19795","volume":"8","author":"TA Gardner","year":"2012","unstructured":"Gardner TA, Elzey BD, Hahn NM (2012) Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Hum Vaccin Immunother 8:534\u2013539. https:\/\/doi.org\/10.4161\/hv.19795","journal-title":"Hum Vaccin Immunother"},{"key":"5329_CR44","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1158\/0008-5472.Can-23-2846","volume":"84","author":"M Okada","year":"2024","unstructured":"Okada M, Yamasaki S, Nakazato H, Hirahara Y, Ishibashi T, Kawamura M, Shimizu K, Fujii SI (2024) ARID1A-deficient tumors acquire immunogenic neoantigens during the development of resistance to targeted therapy. Cancer Res 84:2792\u20132805. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-2846","journal-title":"Cancer Res"},{"key":"5329_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.11.015","volume":"6","author":"AV Yaremenko","year":"2025","unstructured":"Yaremenko AV, Khan MM, Zhen X, Tang Y, Tao W (2025) Clinical advances of mRNA vaccines for cancer immunotherapy. Medicine 6:100562. https:\/\/doi.org\/10.1016\/j.medj.2024.11.015","journal-title":"Medicine"},{"key":"5329_CR46","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/s0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T (2024) Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403:632\u2013644. https:\/\/doi.org\/10.1016\/s0140-6736(23)02268-7","journal-title":"Lancet"},{"key":"5329_CR47","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/jco.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:2780\u20132788. https:\/\/doi.org\/10.1200\/jco.2014.58.3377","journal-title":"J Clin Oncol"},{"key":"5329_CR48","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1039\/d3cs00162h","volume":"53","author":"J Zou","year":"2024","unstructured":"Zou J, Zhang Y, Pan Y, Mao Z, Chen X (2024) Advancing nanotechnology for neoantigen-based cancer theranostics. Chem Soc Rev 53:3224\u20133252. https:\/\/doi.org\/10.1039\/d3cs00162h","journal-title":"Chem Soc Rev"},{"key":"5329_CR49","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N (2021) Therapeutic cancer vaccines. Nat Rev Cancer 21:360\u2013378. https:\/\/doi.org\/10.1038\/s41568-021-00346-0","journal-title":"Nat Rev Cancer"},{"key":"5329_CR50","first-page":"2665","volume":"20","author":"B Bodey","year":"2000","unstructured":"Bodey B, Bodey B Jr, Siegel SE, Kaiser HE (2000) Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res 20:2665\u20132676","journal-title":"Anticancer Res"},{"key":"5329_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imr.12132","volume":"257","author":"CS Hinrichs","year":"2014","unstructured":"Hinrichs CS, Rosenberg SA (2014) Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257:56\u201371. https:\/\/doi.org\/10.1111\/imr.12132","journal-title":"Immunol Rev"},{"key":"5329_CR52","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/nejm198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 319:1676\u20131680. https:\/\/doi.org\/10.1056\/nejm198812223192527","journal-title":"N Engl J Med"},{"key":"5329_CR53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/imr.12126","volume":"257","author":"EJ Cheadle","year":"2014","unstructured":"Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE (2014) CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev 257:91\u2013106. https:\/\/doi.org\/10.1111\/imr.12126","journal-title":"Immunol Rev"},{"key":"5329_CR54","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/imr.12134","volume":"257","author":"C Yee","year":"2014","unstructured":"Yee C (2014) The use of endogenous T cells for adoptive transfer. Immunol Rev 257:250\u2013263. https:\/\/doi.org\/10.1111\/imr.12134","journal-title":"Immunol Rev"},{"key":"5329_CR55","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2217\/imt.14.86","volume":"6","author":"M Wang","year":"2014","unstructured":"Wang M, Yin B, Wang HY, Wang RF (2014) Current advances in T-cell-based cancer immunotherapy. Immunotherapy 6:1265\u20131278. https:\/\/doi.org\/10.2217\/imt.14.86","journal-title":"Immunotherapy"},{"key":"5329_CR56","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126\u2013129. https:\/\/doi.org\/10.1126\/science.1129003","journal-title":"Science"},{"key":"5329_CR57","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19:620\u2013626. https:\/\/doi.org\/10.1038\/mt.2010.272","journal-title":"Mol Ther"},{"key":"5329_CR58","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/jco.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917\u2013924. https:\/\/doi.org\/10.1200\/jco.2010.32.2537","journal-title":"J Clin Oncol"},{"key":"5329_CR59","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","volume":"36","author":"RA Morgan","year":"2013","unstructured":"Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36:133\u2013151. https:\/\/doi.org\/10.1097\/CJI.0b013e3182829903","journal-title":"J Immunother"},{"key":"5329_CR60","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86:10024\u201310028. https:\/\/doi.org\/10.1073\/pnas.86.24.10024","journal-title":"Proc Natl Acad Sci USA"},{"key":"5329_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030663","author":"YJ Chen","year":"2023","unstructured":"Chen YJ, Abila B, Mostafa Kamel Y (2023) CAR-T: what is next? Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15030663","journal-title":"Cancers (Basel)"},{"key":"5329_CR62","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M (2023) Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 141:1675\u20131684. https:\/\/doi.org\/10.1182\/blood.2022018730","journal-title":"Blood"},{"key":"5329_CR63","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/s0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS (2022) Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399:2294\u20132308. https:\/\/doi.org\/10.1016\/s0140-6736(22)00662-6","journal-title":"Lancet"},{"key":"5329_CR64","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Mu\u00f1oz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR (2022) Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 386:640\u2013654. https:\/\/doi.org\/10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"key":"5329_CR65","doi-asserted-by":"publisher","first-page":"750.e1","DOI":"10.1016\/j.jtct.2022.08.010","volume":"28","author":"MA Perales","year":"2022","unstructured":"Perales MA, Kuruvilla J, Snider JT, Vadgama S, Blissett R, El-Moustaid F, Smith NJ, Patel AR, Johnston PB (2022) The cost-effectiveness of axicabtagene ciloleucel as second-line therapy in patients with large B-cell lymphoma in the United States: an economic evaluation of the ZUMA-7 trial. Transplant Cell Ther 28:750.e1-750.e6. https:\/\/doi.org\/10.1016\/j.jtct.2022.08.010","journal-title":"Transplant Cell Ther"},{"key":"5329_CR66","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/s0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517\u2013528. https:\/\/doi.org\/10.1016\/s0140-6736(14)61403-3","journal-title":"Lancet"},{"key":"5329_CR67","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, Gill SI, Loren AW, Tian L, Kulikovskaya I, Gupta M, Ambrose DE, Davis MM, Fraietta JA, Brogdon JL, Young RM, Chew A, Levine BL, Siegel DL, Alanio C, Wherry EJ, Bushman FD, Lacey SF, Tan K, June CH (2022) Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature 602:503\u2013509. https:\/\/doi.org\/10.1038\/s41586-021-04390-6","journal-title":"Nature"},{"key":"5329_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010405","author":"E Guerra","year":"2021","unstructured":"Guerra E, Di Pietro R, Basile M, Trerotola M, Alberti S (2021) Cancer-homing CAR-T cells and endogenous immune population dynamics. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23010405","journal-title":"Int J Mol Sci"},{"key":"5329_CR69","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","volume":"4","author":"M Chmielewski","year":"2013","unstructured":"Chmielewski M, Hombach AA, Abken H (2013) Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol 4:371. https:\/\/doi.org\/10.3389\/fimmu.2013.00371","journal-title":"Front Immunol"},{"key":"5329_CR70","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13:227\u2013242. https:\/\/doi.org\/10.1038\/nri3405","journal-title":"Nat Rev Immunol"},{"key":"5329_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107419","volume":"205","author":"SJ Bagley","year":"2020","unstructured":"Bagley SJ, O\u2019Rourke DM (2020) Clinical investigation of CAR T cells for solid tumors: lessons learned and future directions. Pharmacol Ther 205:107419. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107419","journal-title":"Pharmacol Ther"},{"key":"5329_CR72","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17:1453\u20131464. https:\/\/doi.org\/10.1038\/mt.2009.83","journal-title":"Mol Ther"},{"key":"5329_CR73","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/jci46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121:1822\u20131826. https:\/\/doi.org\/10.1172\/jci46110","journal-title":"J Clin Invest"},{"key":"5329_CR74","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/mt.2009.210","volume":"18","author":"XS Zhong","year":"2010","unstructured":"Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M (2010) Chimeric antigen receptors combining 4\u20131BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther 18:413\u2013420. https:\/\/doi.org\/10.1038\/mt.2009.210","journal-title":"Mol Ther"},{"key":"5329_CR75","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H (2014) Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 257:83\u201390. https:\/\/doi.org\/10.1111\/imr.12125","journal-title":"Immunol Rev"},{"key":"5329_CR76","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ (2012) Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119:4133\u20134141. https:\/\/doi.org\/10.1182\/blood-2011-12-400044","journal-title":"Blood"},{"key":"5329_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744823","volume":"12","author":"H Lin","year":"2021","unstructured":"Lin H, Cheng J, Mu W, Zhou J, Zhu L (2021) Advances in universal CAR-T cell therapy. Front Immunol 12:744823. https:\/\/doi.org\/10.3389\/fimmu.2021.744823","journal-title":"Front Immunol"},{"key":"5329_CR78","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S (2019) Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer 120:26\u201337. https:\/\/doi.org\/10.1038\/s41416-018-0325-1","journal-title":"Br J Cancer"},{"key":"5329_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122381","volume":"337","author":"A Esmaeilzadeh","year":"2024","unstructured":"Esmaeilzadeh A, Hadiloo K, Jabbari M, Elahi R (2024) Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors. Life Sci 337:122381. https:\/\/doi.org\/10.1016\/j.lfs.2023.122381","journal-title":"Life Sci"},{"key":"5329_CR80","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s12094-020-02490-9","volume":"23","author":"S Tahmasebi","year":"2021","unstructured":"Tahmasebi S, Elahi R, Khosh E, Esmaeilzadeh A (2021) Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy. Clin Transl Oncol 23:1003\u20131019. https:\/\/doi.org\/10.1007\/s12094-020-02490-9","journal-title":"Clin Transl Oncol"},{"key":"5329_CR81","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J (2023) Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol 12:14. https:\/\/doi.org\/10.1186\/s40164-023-00373-7","journal-title":"Exp Hematol Oncol"},{"key":"5329_CR82","doi-asserted-by":"publisher","DOI":"10.1063\/5.0073746","volume":"6","author":"Y Wu","year":"2022","unstructured":"Wu Y, Huang Z, Harrison R, Liu L, Zhu L, Situ Y, Wang Y (2022) Engineering CAR T cells for enhanced efficacy and safety. APL Bioeng 6:011502. https:\/\/doi.org\/10.1063\/5.0073746","journal-title":"APL Bioeng"},{"key":"5329_CR83","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1111\/bjh.17197","volume":"192","author":"P Jain","year":"2021","unstructured":"Jain P, Nastoupil L, Westin J, Lee HJ, Navsaria L, Steiner RE, Ahmed S, Moghrabi O, Oriabure O, Chen W, Badillo M, Flowers CR, Wang ML (2021) Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol 192:e38\u2013e42. https:\/\/doi.org\/10.1111\/bjh.17197","journal-title":"Br J Haematol"},{"key":"5329_CR84","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507\u20131517. https:\/\/doi.org\/10.1056\/NEJMoa1407222","journal-title":"N Engl J Med"},{"key":"5329_CR85","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","volume":"8","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M (2018) The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B 8:539\u2013551. https:\/\/doi.org\/10.1016\/j.apsb.2018.03.001","journal-title":"Acta Pharm Sin B"},{"key":"5329_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205108","author":"F Boccalatte","year":"2022","unstructured":"Boccalatte F, Mina R, Aroldi A, Leone S, Suryadevara CM, Placantonakis DG, Bruno B (2022) Advances and hurdles in CAR T cell immune therapy for solid tumors. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14205108","journal-title":"Cancers (Basel)"},{"key":"5329_CR87","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK (2019) CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 10:128. https:\/\/doi.org\/10.3389\/fimmu.2019.00128","journal-title":"Front Immunol"},{"key":"5329_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040615","author":"L Buonaguro","year":"2020","unstructured":"Buonaguro L, Tagliamonte M (2020) Selecting target antigens for cancer vaccine development. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines8040615","journal-title":"Vaccines (Basel)"},{"key":"5329_CR89","doi-asserted-by":"publisher","first-page":"264","DOI":"10.18502\/ijaai.v19i3.3454","volume":"19","author":"L Jafarzadeh","year":"2020","unstructured":"Jafarzadeh L, Masoumi E, Alishah K, Mirzaei HR, Jamali A, Fallah-Mehrjardi K, Rostamian H, Khakpoor-Koosheh M, Meshkani R, Noorbakhsh F, Hadjati J (2020) Construction and functional characterization of a fully human anti-mesothelin chimeric antigen receptor (CAR) expressing T cell. Iran J Allergy Asthma Immunol 19:264\u2013275. https:\/\/doi.org\/10.18502\/ijaai.v19i3.3454","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"5329_CR90","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-019-0704-y","volume":"12","author":"J Lv","year":"2019","unstructured":"Lv J, Zhao R, Wu D, Zheng D, Wu Z, Shi J, Wei X, Wu Q, Long Y, Lin S, Wang S, Wang Z, Li Y, Chen Y, He Q, Chen S, Yao H, Liu Z, Tang Z, Yao Y, Pei D, Liu P, Zhang X, Zhang Z, Cui S, Chen R, Li P (2019) Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. J Hematol Oncol 12:18. https:\/\/doi.org\/10.1186\/s13045-019-0704-y","journal-title":"J Hematol Oncol"},{"key":"5329_CR91","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1002\/jcb.27776","volume":"120","author":"M Sotoudeh","year":"2019","unstructured":"Sotoudeh M, Shirvani SI, Merat S, Ahmadbeigi N, Naderi M (2019) MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma. J Cell Biochem 120:5010\u20135017. https:\/\/doi.org\/10.1002\/jcb.27776","journal-title":"J Cell Biochem"},{"key":"5329_CR92","doi-asserted-by":"publisher","first-page":"2029298","DOI":"10.1080\/2162402x.2022.2029298","volume":"11","author":"M Hagiwara","year":"2022","unstructured":"Hagiwara M, Fushimi A, Bhattacharya A, Yamashita N, Morimoto Y, Oya M, Withers HG, Hu Q, Liu T, Liu S, Wong KK, Long MD, Kufe D (2022) MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. Oncoimmunology 11:2029298. https:\/\/doi.org\/10.1080\/2162402x.2022.2029298","journal-title":"Oncoimmunology"},{"key":"5329_CR93","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/cji.0000000000000460","volume":"46","author":"L Mao","year":"2023","unstructured":"Mao L, Su S, Li J, Yu S, Gong Y, Chen C, Hu Z, Huang X (2023) Development of engineered CAR T cells targeting tumor-associated glycoforms of MUC1 for the treatment of intrahepatic cholangiocarcinoma. J Immunother 46:89\u201395. https:\/\/doi.org\/10.1097\/cji.0000000000000460","journal-title":"J Immunother"},{"key":"5329_CR94","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.2174\/1389557516666160321114917","volume":"16","author":"D Singh","year":"2016","unstructured":"Singh D, Attri BK, Gill RK, Bariwal J (2016) Review on EGFR inhibitors: critical updates. Mini Rev Med Chem 16:1134\u20131166. https:\/\/doi.org\/10.2174\/1389557516666160321114917","journal-title":"Mini Rev Med Chem"},{"key":"5329_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.713158","volume":"12","author":"MB Fuertes","year":"2021","unstructured":"Fuertes MB, Domaica CI, Zwirner NW (2021) Leveraging NKG2D ligands in immuno-oncology. Front Immunol 12:713158. https:\/\/doi.org\/10.3389\/fimmu.2021.713158","journal-title":"Front Immunol"},{"key":"5329_CR96","first-page":"2064","volume":"9","author":"H Liu","year":"2019","unstructured":"Liu H, Wang S, Xin J, Wang J, Yao C, Zhang Z (2019) Role of NKG2D and its ligands in cancer immunotherapy. Am J Cancer Res 9:2064\u20132078","journal-title":"Am J Cancer Res"},{"key":"5329_CR97","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3389\/fimmu.2018.00476","volume":"9","author":"A Zingoni","year":"2018","unstructured":"Zingoni A, Molfetta R, Fionda C, Soriani A, Paolini R, Cippitelli M, Cerboni C, Santoni A (2018) NKG2D and its ligands: \u201cone for all, all for one.\u201d Front Immunol 9:476. https:\/\/doi.org\/10.3389\/fimmu.2018.00476","journal-title":"Front Immunol"},{"key":"5329_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092128","author":"F Fagotto","year":"2020","unstructured":"Fagotto F (2020) EpCAM as modulator of tissue plasticity. Cells. https:\/\/doi.org\/10.3390\/cells9092128","journal-title":"Cells"},{"key":"5329_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061361","author":"A Gaber","year":"2020","unstructured":"Gaber A, Lenar\u010di\u010d B, Pav\u0161i\u010d M (2020) Current view on EpCAM structural biology. Cells. https:\/\/doi.org\/10.3390\/cells9061361","journal-title":"Cells"},{"key":"5329_CR100","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10555-020-09898-3","volume":"39","author":"O Gires","year":"2020","unstructured":"Gires O, Pan M, Schinke H, Canis M, Baeuerle PA (2020) Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? Cancer Metastasis Rev 39:969\u2013987. https:\/\/doi.org\/10.1007\/s10555-020-09898-3","journal-title":"Cancer Metastasis Rev"},{"key":"5329_CR101","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","volume":"10","author":"P Singh","year":"2017","unstructured":"Singh P, Toom S, Huang Y (2017) Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol 10:105. https:\/\/doi.org\/10.1186\/s13045-017-0473-4","journal-title":"J Hematol Oncol"},{"key":"5329_CR102","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1128\/mcb.21.21.7380-7390.2001","volume":"21","author":"T Niimi","year":"2001","unstructured":"Niimi T, Nagashima K, Ward JM, Minoo P, Zimonjic DB, Popescu NC, Kimura S (2001) claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol Cell Biol 21:7380\u20137390. https:\/\/doi.org\/10.1128\/mcb.21.21.7380-7390.2001","journal-title":"Mol Cell Biol"},{"key":"5329_CR103","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.Ccr-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, Huber C, T\u00fcreci O (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14:7624\u20137634. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-08-1547","journal-title":"Clin Cancer Res"},{"key":"5329_CR104","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","volume":"481","author":"O T\u00fcreci","year":"2011","unstructured":"T\u00fcreci O, Koslowski M, Helftenbein G, Castle J, Rohde C, Dhaene K, Seitz G, Sahin U (2011) Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene 481:83\u201392. https:\/\/doi.org\/10.1016\/j.gene.2011.04.007","journal-title":"Gene"},{"key":"5329_CR105","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1053\/j.gastro.2011.10.040","volume":"142","author":"D Hayashi","year":"2012","unstructured":"Hayashi D, Tamura A, Tanaka H, Yamazaki Y, Watanabe S, Suzuki K, Suzuki K, Sentani K, Yasui W, Rakugi H, Isaka Y, Tsukita S (2012) Deficiency of claudin-18 causes paracellular H+ leakage, up-regulation of interleukin-1\u03b2, and atrophic gastritis in mice. Gastroenterology 142:292\u2013304. https:\/\/doi.org\/10.1053\/j.gastro.2011.10.040","journal-title":"Gastroenterology"},{"key":"5329_CR106","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1523096","volume":"8","author":"\u04e6 T\u00fcreci","year":"2019","unstructured":"T\u00fcreci \u04e6, Mitnacht-Kraus R, W\u00f6ll S, Yamada T, Sahin U (2019) Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology 8:e1523096. https:\/\/doi.org\/10.1080\/2162402x.2018.1523096","journal-title":"Oncoimmunology"},{"key":"5329_CR107","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","volume":"25","author":"C Zhang","year":"2017","unstructured":"Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, Zhang R, Xiong Z, Wei Z, Shen J, Luo Y, Zhang Q, Liu L, Qin H, Liu W, Wu F, Chen W, Pan F, Zhang X, Bie P, Liang H, Pecher G, Qian C (2017) Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol Ther 25:1248\u20131258. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.010","journal-title":"Mol Ther"},{"key":"5329_CR108","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fonc.2019.00248","volume":"9","author":"Y Shimizu","year":"2019","unstructured":"Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T (2019) Next-generation cancer immunotherapy targeting glypican-3. Front Oncol 9:248. https:\/\/doi.org\/10.3389\/fonc.2019.00248","journal-title":"Front Oncol"},{"key":"5329_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091339","author":"T Nishida","year":"2019","unstructured":"Nishida T, Kataoka H (2019) Glypican 3-targeted therapy in hepatocellular carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11091339","journal-title":"Cancers (Basel)"},{"key":"5329_CR110","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/85339","volume":"2","author":"AI Chapoval","year":"2001","unstructured":"Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, Chen L (2001) B7\u2013H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2:269\u2013274. https:\/\/doi.org\/10.1038\/85339","journal-title":"Nat Immunol"},{"key":"5329_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701006","volume":"12","author":"WT Zhou","year":"2021","unstructured":"Zhou WT, Jin WL (2021) B7\u2013H3\/CD276: an emerging cancer immunotherapy. Front Immunol 12:701006. https:\/\/doi.org\/10.3389\/fimmu.2021.701006","journal-title":"Front Immunol"},{"key":"5329_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","volume":"155","author":"J Jacobs","year":"2015","unstructured":"Jacobs J, Deschoolmeester V, Zwaenepoel K, Rolfo C, Silence K, Rottey S, Lardon F, Smits E, Pauwels P (2015) CD70: an emerging target in cancer immunotherapy. Pharmacol Ther 155:1\u201310. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.07.007","journal-title":"Pharmacol Ther"},{"key":"5329_CR113","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1182\/blood-2016-12-756585","volume":"130","author":"MF Al Sayed","year":"2017","unstructured":"Al Sayed MF, Ruckstuhl CA, Hilmenyuk T, Claus C, Bourquin JP, Bornhauser BC, Radpour R, Riether C, Ochsenbein AF (2017) CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies. Blood 130:297\u2013309. https:\/\/doi.org\/10.1182\/blood-2016-12-756585","journal-title":"Blood"},{"key":"5329_CR114","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1189\/jlb.1003508","volume":"76","author":"P Garc\u00eda","year":"2004","unstructured":"Garc\u00eda P, De Heredia AB, Bell\u00f3n T, Carpio E, Llano M, Caparr\u00f3s E, Aparicio P, L\u00f3pez-Botet M (2004) Signalling via CD70, a member of the TNF family, regulates T cell functions. J Leukoc Biol 76:263\u2013270. https:\/\/doi.org\/10.1189\/jlb.1003508","journal-title":"J Leukoc Biol"},{"key":"5329_CR115","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, Kochanek M, B\u00f6ll B, von Bergwelt-Baildon MS (2018) Cytokine release syndrome. J Immunother Cancer 6:56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"key":"5329_CR116","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1188\/17.Cjon.S2.29-34","volume":"21","author":"L Smith","year":"2017","unstructured":"Smith L, Venella K (2017) Cytokine release syndrome: inpatient care for side effects of CAR T-cell therapy. Clin J Oncol Nurs 21:29\u201334. https:\/\/doi.org\/10.1188\/17.Cjon.S2.29-34","journal-title":"Clin J Oncol Nurs"},{"key":"5329_CR117","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41417-024-00823-2","volume":"31","author":"W Xiao","year":"2024","unstructured":"Xiao W, Xu L, Wang J, Yu K, Xu B, Que Y, Zhao J, Pan Q, Gao C, Zhou P, Zhang X (2024) FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma. Cancer Gene Ther 31:1571\u20131584. https:\/\/doi.org\/10.1038\/s41417-024-00823-2","journal-title":"Cancer Gene Ther"},{"key":"5329_CR118","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/bloodadvances.2019001287","volume":"4","author":"AHJ Tan","year":"2020","unstructured":"Tan AHJ, Vinanica N, Campana D (2020) Chimeric antigen receptor-T cells with cytokine neutralizing capacity. Blood Adv 4:1419\u20131431. https:\/\/doi.org\/10.1182\/bloodadvances.2019001287","journal-title":"Blood Adv"},{"key":"5329_CR119","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/mop.0000000000000747","volume":"31","author":"DE Baymon","year":"2019","unstructured":"Baymon DE, Boyer EW (2019) Chimeric antigen receptor T-cell toxicity. Curr Opin Pediatr 31:251\u2013255. https:\/\/doi.org\/10.1097\/mop.0000000000000747","journal-title":"Curr Opin Pediatr"},{"key":"5329_CR120","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN (2023) Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther 29:438.e1-438.e16. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.006","journal-title":"Transplant Cell Ther"},{"key":"5329_CR121","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","volume":"56","author":"VS Sheth","year":"2021","unstructured":"Sheth VS, Gauthier J (2021) Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant 56:552\u2013566. https:\/\/doi.org\/10.1038\/s41409-020-01134-4","journal-title":"Bone Marrow Transplant"},{"key":"5329_CR122","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park JH, Nath K, Devlin SM, Sauter CS, Palomba ML, Shah G, Dahi P, Lin RJ, Scordo M, Perales MA, Shouval R, Tomas AA, Cathcart E, Mead E, Santomasso B, Holodny A, Brentjens RJ, Riviere I, Sadelain M (2023) CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med 29:1710\u20131717. https:\/\/doi.org\/10.1038\/s41591-023-02404-6","journal-title":"Nat Med"},{"key":"5329_CR123","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/bloodadvances.2024013688","volume":"9","author":"A Bajwa","year":"2025","unstructured":"Bajwa A, Zhao Q, Geer M, Lin C, Westholder J, Maakaron J, Ghosh M, Frame D, Galal A, Tossey J, Ahmed N, Bezerra E, Denlinger N, de Lima M, Epperla N, Caimi P, Voorhees T (2025) Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis. Blood Adv 9:170\u2013175. https:\/\/doi.org\/10.1182\/bloodadvances.2024013688","journal-title":"Blood Adv"},{"key":"5329_CR124","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27671","author":"Z Hou","year":"2025","unstructured":"Hou Z, Jiang Y, Fu Y, Ruan M, Meng D, Li Y, Zhao D, Yang J, Long Z, Ge J (2025) Cyclophosphamide abrogates immune effector cell-associated neurotoxicity syndrome associated with CAR-T cell therapy. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.27671","journal-title":"Am J Hematol"},{"key":"5329_CR125","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.ymthe.2017.03.002","volume":"25","author":"J Fisher","year":"2017","unstructured":"Fisher J, Abramowski P, Wisidagamage Don ND, Flutter B, Capsomidis A, Cheung GW, Gustafsson K, Anderson J (2017) Avoidance of on-target off-tumor activation using a co-stimulation-only chimeric antigen receptor. Mol Ther 25:1234\u20131247. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.002","journal-title":"Mol Ther"},{"key":"5329_CR126","doi-asserted-by":"publisher","first-page":"2386187","DOI":"10.1155\/2018\/2386187","volume":"2018","author":"S Sun","year":"2018","unstructured":"Sun S, Hao H, Yang G, Zhang Y, Fu Y (2018) Immunotherapy with CAR-modified T cells: toxicities and overcoming strategies. J Immunol Res 2018:2386187. https:\/\/doi.org\/10.1155\/2018\/2386187","journal-title":"J Immunol Res"},{"key":"5329_CR127","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, Walker WJ, McNally KA, Lim WA (2016) Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167:419-432.e16. https:\/\/doi.org\/10.1016\/j.cell.2016.09.011","journal-title":"Cell"},{"key":"5329_CR128","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006597","author":"VD Fedorov","year":"2013","unstructured":"Fedorov VD, Themeli M, Sadelain M (2013) PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.3006597","journal-title":"Sci Transl Med"},{"key":"5329_CR129","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, Nabavizadeh A, Jarocha D, Martins R, Maloney E, Lledo L, Stein C, Marshall A, Leskowitz R, Jadlowsky JK, Christensen S, Oner BS, Plesa G, Brennan A, Gonzalez V, Chen F, Sun Y, Gladney W, Barrett D, Nasrallah MP, Hwang WT, Ming GL, Song H, Siegel DL, June CH, Hexner EO, Binder ZA, O\u2019Rourke DM (2024) Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med 30:1320\u20131329. https:\/\/doi.org\/10.1038\/s41591-024-02893-z","journal-title":"Nat Med"},{"key":"5329_CR130","unstructured":"Inc. AB (2024) A study to evaluate the safety and efficacy of A2B694, a logic-gated CAR T, in participants with solid tumors that express MSLN and have lost HLA-A*02 expression (EVEREST-2)"},{"key":"5329_CR131","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M (2019) Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med 25:82\u201388. https:\/\/doi.org\/10.1038\/s41591-018-0290-5","journal-title":"Nat Med"},{"key":"5329_CR132","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1158\/2326-6066.Cir-19-0908","volume":"8","author":"D Wijewarnasuriya","year":"2020","unstructured":"Wijewarnasuriya D, Bebernitz C, Lopez AV, Rafiq S, Brentjens RJ (2020) Excessive costimulation leads to dysfunction of adoptively transferred T cells. Cancer Immunol Res 8:732\u2013742. https:\/\/doi.org\/10.1158\/2326-6066.Cir-19-0908","journal-title":"Cancer Immunol Res"},{"key":"5329_CR133","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder NW, Blair IA, Milone MC, June CH (2016) Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44:380\u2013390. https:\/\/doi.org\/10.1016\/j.immuni.2016.01.021","journal-title":"Immunity"},{"key":"5329_CR134","doi-asserted-by":"publisher","first-page":"7647","DOI":"10.4049\/jimmunol.173.12.7647","volume":"173","author":"M Chmielewski","year":"2004","unstructured":"Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H (2004) T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 173:7647\u20137653. https:\/\/doi.org\/10.4049\/jimmunol.173.12.7647","journal-title":"J Immunol"},{"key":"5329_CR135","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ymthe.2018.01.020","volume":"26","author":"W Xiong","year":"2018","unstructured":"Xiong W, Chen Y, Kang X, Chen Z, Zheng P, Hsu YH, Jang JH, Qin L, Liu H, Dotti G, Liu D (2018) Immunological synapse predicts effectiveness of chimeric antigen receptor cells. Mol Ther 26:963\u2013975. https:\/\/doi.org\/10.1016\/j.ymthe.2018.01.020","journal-title":"Mol Ther"},{"key":"5329_CR136","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003354","author":"E Roselli","year":"2021","unstructured":"Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, Cervantes EV, Bulliard Y, Tu N, Lee SB, Yu B, Locke FL, Davila ML (2021) 4\u20131BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-003354","journal-title":"J Immunother Cancer"},{"key":"5329_CR137","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12967-025-06276-x","volume":"23","author":"Z Wu","year":"2025","unstructured":"Wu Z, Wang H, Zheng Z, Lin Y, Bian L, Geng H, Huang X, Zhu J, Jing H, Zhang Y, Ji C, Zhai B (2025) IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment. J Transl Med 23:275. https:\/\/doi.org\/10.1186\/s12967-025-06276-x","journal-title":"J Transl Med"},{"key":"5329_CR138","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ccell.2024.12.001","volume":"43","author":"S Ma","year":"2025","unstructured":"Ma S, Ong LT, Jiang Z, Lee WC, Lee PL, Yusuf M, Ditzel HJ, Wang Y, Chen Q, Wang W, Wu X, Tan EY, Yu Q (2025) Targeting P4HA1 promotes CD8(+) T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. Cancer Cell 43:213-231.e9. https:\/\/doi.org\/10.1016\/j.ccell.2024.12.001","journal-title":"Cancer Cell"},{"key":"5329_CR139","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40164-025-00609-8","volume":"14","author":"Y Kim","year":"2025","unstructured":"Kim Y, Jeun M, Lee HK, Choi JU, Park S, Park CH (2025) TET2 downregulation enhances the antitumor efficacy of CD19 CAR T cells in a preclinical model. Exp Hematol Oncol 14:23. https:\/\/doi.org\/10.1186\/s40164-025-00609-8","journal-title":"Exp Hematol Oncol"},{"key":"5329_CR140","doi-asserted-by":"publisher","first-page":"eadk2954","DOI":"10.1126\/sciimmunol.adk2954","volume":"9","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Luo Y, Lou G, Yihunie K, Wizzard S, DeVilbiss AW, Muh S, Ma C, Shinde SS, Hoar J, Hu T, Zhang N, Biswal S, DeBerardinis RJ, Wu T, Yao C (2024) The redox sensor KEAP1 facilitates adaptation of T cells to chronic antigen stimulation by preventing hyperactivation. Sci Immunol 9:eadk2954. https:\/\/doi.org\/10.1126\/sciimmunol.adk2954","journal-title":"Sci Immunol"},{"key":"5329_CR141","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008429","author":"W Ouyang","year":"2024","unstructured":"Ouyang W, Jin SW, Xu N, Liu WY, Zhao H, Zhang L, Kang L, Tao Y, Liu Y, Wang Y, Wang J, Liu F, Yu L, Liu Z, Mi JQ (2024) PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-008429","journal-title":"J Immunother Cancer"},{"key":"5329_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044197","author":"K Cheng","year":"2023","unstructured":"Cheng K, Feng X, Chai Z, Wang Z, Liu Z, Yan Z, Wang Y, Zhang S (2023) 4\u20131BB-based CAR T cells effectively reverse exhaustion and enhance the anti-tumor immune response through autocrine PD-L1 scFv antibody. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24044197","journal-title":"Int J Mol Sci"},{"key":"5329_CR143","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423\u20131437. https:\/\/doi.org\/10.1038\/nm.3394","journal-title":"Nat Med"},{"key":"5329_CR144","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11427-019-9665-8","volume":"63","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Xiao X, Saw PE, Wu W, Huang H, Chen J, Nie Y (2020) Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Sci China Life Sci 63:180\u2013205. https:\/\/doi.org\/10.1007\/s11427-019-9665-8","journal-title":"Sci China Life Sci"},{"key":"5329_CR145","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/eji.201847659","volume":"49","author":"A Tanaka","year":"2019","unstructured":"Tanaka A, Sakaguchi S (2019) Targeting Treg cells in cancer immunotherapy. Eur J Immunol 49:1140\u20131146. https:\/\/doi.org\/10.1002\/eji.201847659","journal-title":"Eur J Immunol"},{"key":"5329_CR146","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.coph.2009.06.014","volume":"9","author":"S Ugel","year":"2009","unstructured":"Ugel S, Delpozzo F, Desantis G, Papalini F, Simonato F, Sonda N, Zilio S, Bronte V (2009) Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 9:470\u2013481. https:\/\/doi.org\/10.1016\/j.coph.2009.06.014","journal-title":"Curr Opin Pharmacol"},{"key":"5329_CR147","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24:541\u2013550. https:\/\/doi.org\/10.1038\/s41591-018-0014-x","journal-title":"Nat Med"},{"key":"5329_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118300","volume":"260","author":"F Guo","year":"2020","unstructured":"Guo F, Cui J (2020) CAR-T in solid tumors: blazing a new trail through the brambles. Life Sci 260:118300. https:\/\/doi.org\/10.1016\/j.lfs.2020.118300","journal-title":"Life Sci"},{"key":"5329_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.788211","volume":"12","author":"M Abdoli Shadbad","year":"2021","unstructured":"Abdoli Shadbad M, Hemmat N, Khaze Shahgoli V, Derakhshani A, Baradaran F, Brunetti O, Fasano R, Bernardini R, Silvestris N, Baradaran B (2021) A systematic review on PD-1 blockade and PD-1 gene-editing of CAR-T cells for glioma therapy: from deciphering to personalized medicine. Front Immunol 12:788211. https:\/\/doi.org\/10.3389\/fimmu.2021.788211","journal-title":"Front Immunol"},{"key":"5329_CR150","doi-asserted-by":"publisher","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, Aghebati-Maleki L, Baradaran B (2023) The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front Immunol 14:1113882. https:\/\/doi.org\/10.3389\/fimmu.2023.1113882","journal-title":"Front Immunol"},{"key":"5329_CR151","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS (2016) Fundamentals of cancer metabolism. Sci Adv 2:e1600200. https:\/\/doi.org\/10.1126\/sciadv.1600200","journal-title":"Sci Adv"},{"key":"5329_CR152","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3389\/fimmu.2018.01104","volume":"9","author":"P Kosti","year":"2018","unstructured":"Kosti P, Maher J, Arnold JN (2018) Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors. Front Immunol 9:1104. https:\/\/doi.org\/10.3389\/fimmu.2018.01104","journal-title":"Front Immunol"},{"key":"5329_CR153","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.4049\/jimmunol.168.8.3771","volume":"168","author":"AL Mellor","year":"2002","unstructured":"Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH (2002) Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 168:3771\u20133776. https:\/\/doi.org\/10.4049\/jimmunol.168.8.3771","journal-title":"J Immunol"},{"key":"5329_CR154","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fimmu.2017.00045","volume":"8","author":"A Ager","year":"2017","unstructured":"Ager A (2017) High endothelial venules and other blood vessels: critical regulators of lymphoid organ development and function. Front Immunol 8:45. https:\/\/doi.org\/10.3389\/fimmu.2017.00045","journal-title":"Front Immunol"},{"key":"5329_CR155","doi-asserted-by":"publisher","first-page":"10634","DOI":"10.1038\/s41598-019-46938-7","volume":"9","author":"Y Vedvyas","year":"2019","unstructured":"Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Zarnegar R, Hsu YS, Hsu JM, Van Besien K, Gaudet I, Law P, Kim NJ, Hofe EV, Jin MM (2019) Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci Rep 9:10634. https:\/\/doi.org\/10.1038\/s41598-019-46938-7","journal-title":"Sci Rep"},{"key":"5329_CR156","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1007\/s10565-023-09821-w","volume":"39","author":"LL Lu","year":"2023","unstructured":"Lu LL, Xiao SX, Lin ZY, Bai JJ, Li W, Song ZQ, Zhou YH, Lu B, Wu WZ (2023) GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy. Cell Biol Toxicol 39:3101\u20133119. https:\/\/doi.org\/10.1007\/s10565-023-09821-w","journal-title":"Cell Biol Toxicol"},{"key":"5329_CR157","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","volume":"14","author":"N Pang","year":"2021","unstructured":"Pang N, Shi J, Qin L, Chen A, Tang Y, Yang H, Huang Y, Wu Q, Li X, He B, Li T, Liang B, Zhang J, Cao B, Liu M, Feng Y, Ye X, Chen X, Wang L, Tian Y, Li H, Li J, Hu H, He J, Hu Y, Zhi C, Tang Z, Gong Y, Xu F, Xu L, Fan W, Zhao M, Chen D, Lian H, Yang L, Li P, Zhang Z (2021) IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. J Hematol Oncol 14:118. https:\/\/doi.org\/10.1186\/s13045-021-01128-9","journal-title":"J Hematol Oncol"},{"key":"5329_CR158","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1038\/s41467-023-42634-3","volume":"14","author":"H Wu","year":"2023","unstructured":"Wu H, Zhao X, Hochrein SM, Eckstein M, Gubert GF, Kn\u00f6pper K, Mansilla AM, \u00d6ner A, Doucet-Ladev\u00e8ze R, Schmitz W, Ghesqui\u00e8re B, Theurich S, Dudek J, Gasteiger G, Zernecke A, Kobold S, Kastenm\u00fcller W, Vaeth M (2023) Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1\u03b1-mediated glycolytic reprogramming. Nat Commun 14:6858. https:\/\/doi.org\/10.1038\/s41467-023-42634-3","journal-title":"Nat Commun"},{"key":"5329_CR159","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s11427-016-5027-4","volume":"59","author":"BL Zhang","year":"2016","unstructured":"Zhang BL, Qin DY, Mo ZM, Li Y, Wei W, Wang YS, Wang W, Wei YQ (2016) Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Sci China Life Sci 59:340\u2013348. https:\/\/doi.org\/10.1007\/s11427-016-5027-4","journal-title":"Sci China Life Sci"},{"key":"5329_CR160","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G (2015) Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med 21:524\u2013529. https:\/\/doi.org\/10.1038\/nm.3833","journal-title":"Nat Med"},{"key":"5329_CR161","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1046\/j.1365-3083.2000.00668.x","volume":"51","author":"AM Barfoed","year":"2000","unstructured":"Barfoed AM, Petersen TR, Kirkin AF, Thor Straten P, Claesson MH, Zeuthen J (2000) Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365\u201373 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol 51:128\u2013133. https:\/\/doi.org\/10.1046\/j.1365-3083.2000.00668.x","journal-title":"Scand J Immunol"},{"key":"5329_CR162","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.omto.2019.04.003","volume":"13","author":"V Sivanandam","year":"2019","unstructured":"Sivanandam V, LaRocca CJ, Chen NG, Fong Y, Warner SG (2019) Oncolytic viruses and immune checkpoint inhibition: the best of both worlds. Mol Ther Oncolytics 13:93\u2013106. https:\/\/doi.org\/10.1016\/j.omto.2019.04.003","journal-title":"Mol Ther Oncolytics"},{"key":"5329_CR163","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00251-018-1083-1","volume":"71","author":"I van Belzen","year":"2019","unstructured":"van Belzen I, Kesmir C (2019) Immune biomarkers for predicting response to adoptive cell transfer as cancer treatment. Immunogenetics 71:71\u201386. https:\/\/doi.org\/10.1007\/s00251-018-1083-1","journal-title":"Immunogenetics"},{"key":"5329_CR164","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.it.2018.04.005","volume":"39","author":"CH Lee","year":"2018","unstructured":"Lee CH, Yelensky R, Jooss K, Chan TA (2018) Update on tumor neoantigens and their utility: why it is good to be different. Trends Immunol 39:536\u2013548. https:\/\/doi.org\/10.1016\/j.it.2018.04.005","journal-title":"Trends Immunol"},{"key":"5329_CR165","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.aad1253","volume":"350","author":"E Tran","year":"2015","unstructured":"Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA (2015) Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350:1387\u20131390. https:\/\/doi.org\/10.1126\/science.aad1253","journal-title":"Science"},{"key":"5329_CR166","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV (2017) A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984","journal-title":"Sci Transl Med"},{"key":"5329_CR167","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15:81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166","journal-title":"Nat Rev Clin Oncol"},{"key":"5329_CR168","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843\u2013851. https:\/\/doi.org\/10.1038\/mt.2010.24","journal-title":"Mol Ther"},{"key":"5329_CR169","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1186\/s12885-020-07180-x","volume":"20","author":"T Li","year":"2020","unstructured":"Li T, Wang J (2020) Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice. BMC Cancer 20:678. https:\/\/doi.org\/10.1186\/s12885-020-07180-x","journal-title":"BMC Cancer"},{"key":"5329_CR170","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1073\/pnas.1524155113","volume":"113","author":"DT Rodgers","year":"2016","unstructured":"Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, Schulman A, Du J, Wang F, Singer O, Ma J, Nunez V, Shen J, Woods AK, Wright TM, Schultz PG, Kim CH, Young TS (2016) Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci USA 113:E459\u2013E468. https:\/\/doi.org\/10.1073\/pnas.1524155113","journal-title":"Proc Natl Acad Sci USA"},{"key":"5329_CR171","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1126\/science.add7034","volume":"382","author":"RL Vincent","year":"2023","unstructured":"Vincent RL, Gurbatri CR, Li F, Vardoshvili A, Coker C, Im J, Ballister ER, Rouanne M, Savage T, de Santos-Alexis Los K, Redenti A, Brockmann L, Komaranchath M, Arpaia N, Danino T (2023) Probiotic-guided CAR-T cells for solid tumor targeting. Science 382:211\u2013218. https:\/\/doi.org\/10.1126\/science.add7034","journal-title":"Science"},{"key":"5329_CR172","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole OO, Bouabdallah K, Mu\u00f1oz J, De Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney PA, Goy AH, Kersten MJ, Jacobson CA, Farooq U, Minnema MC, Thieblemont C, Timmerman JM, Stiff P, Avivi I, Tzachanis D, Kim JJ, Bashir Z, McLeroy J, Zheng Y, Rossi JM, Johnson L, Goyal L, van Meerten T (2021) Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol 194:690\u2013700. https:\/\/doi.org\/10.1111\/bjh.17527","journal-title":"Br J Haematol"},{"key":"5329_CR173","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","volume":"9","author":"J Yang","year":"2018","unstructured":"Yang J, Yan J, Liu B (2018) Targeting VEGF\/VEGFR to modulate antitumor immunity. Front Immunol 9:978. https:\/\/doi.org\/10.3389\/fimmu.2018.00978","journal-title":"Front Immunol"},{"key":"5329_CR174","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K (2018) IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 36:346\u2013351. https:\/\/doi.org\/10.1038\/nbt.4086","journal-title":"Nat Biotechnol"},{"key":"5329_CR175","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","volume":"31","author":"G Wang","year":"2023","unstructured":"Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X, Li H, Lu Q, Wu Z, Yuan B, Zheng M, Cheng P, Tong A, Zhou L (2023) CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther 31:134\u2013153. https:\/\/doi.org\/10.1016\/j.ymthe.2022.08.021","journal-title":"Mol Ther"},{"key":"5329_CR176","doi-asserted-by":"publisher","first-page":"eabn2231","DOI":"10.1126\/scitranslmed.abn2231","volume":"14","author":"L Evgin","year":"2022","unstructured":"Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, Moore M, Michael J, Driscoll C, Pulido J, Swanson E, Kennedy R, Coffey M, Loghmani H, Sanchez-Perez L, Olivier G, Harrington K, Pandha H, Melcher A, Diaz RM, Vile RG (2022) Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Transl Med 14:eabn2231. https:\/\/doi.org\/10.1126\/scitranslmed.abn2231","journal-title":"Sci Transl Med"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05329-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-025-05329-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05329-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:47:42Z","timestamp":1760168862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-025-05329-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":176,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["5329"],"URL":"https:\/\/doi.org\/10.1007\/s11010-025-05329-5","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}